TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03918915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 1
Description: Sterile topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 1
Description: Sterile topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 2
Description: Sterile topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 2
Description: Sterile topical ophthalmic solution
Study: NCT05060406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY06006
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY06006
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
Study: NCT03639194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-011
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-011
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-011
Description: Intravenous
Study: NCT03413618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: 600 mg q.d. for 12 month
Study: NCT03918915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYD-101 Dose 2
Description: Sterile topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Sterile topical ophthalmic solution without active ingredient
Study: NCT03413618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compression stockings
Description: above knee stocking for 12 month
Study: NCT03639194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-011
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous
Study: NCT03413618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression stockings
Description: above knee stocking for 12 month
Study: NCT00934661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Epidural Morphine (EREM)
Description: A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
Study: NCT01334281

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
Study: NCT01321086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: 9 sessions of MI from baseline to six months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: 9 sessions of PACE delivered from baseline to six months
Study: NCT02035891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colchicine 0.5mg/d
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 0.5mg/d
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Study: NCT05098678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: 120 mg each tablet containing 30 mg elemental zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
Study: NCT03918915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Sterile topical ophthalmic solution without active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Sterile topical ophthalmic solution without active ingredient
Study: NCT04287387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage 500Mg Tablet
Description: 0.5g three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets
Description: 50mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin tablet
Description: 100mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Tablet
Description: 10mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Tablets
Description: 30mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets
Description: 2mg once daily
Study: NCT03355066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 tablets to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 tablets to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 tablets to be administered orally.
Study: NCT04067258

Intervention type: DIAGNOSTIC_TEST
Intervention: EDI-OCT
Description: EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged.

Intervention type: DIAGNOSTIC_TEST
Intervention: EDI-OCT
Description: EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged.
Study: NCT02115763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04165850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Ciprofloxacin/Celecoxib
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
Study: NCT00749723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
Study: NCT01749722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviAid™ G-Eye procedure
Description: NaviAid™ G-Eye procedure
Study: NCT02588924

Intervention type: OTHER
Intervention: Second University of Naples
Description: enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.

Intervention type: OTHER
Intervention: Neuromed IRCCS
Description: enrollment of patients with Parkinson's disease; collection of blood samples;
Study: NCT01515969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib lactate
Description: Given PO
Study: NCT04685304

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Testing
Description: Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Consultation Note
Description: Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed pharmacogenetic testing
Description: Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
Study: NCT03179085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Kidney Care
Description: All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Kidney Care
Description: All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
Study: NCT01231581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Study: NCT04025528

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Weight loss surgery with either gastric sleeve or gastric bypass surgery

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Weight loss surgery with either gastric sleeve or gastric bypass surgery
Study: NCT03508856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Picato®) 0.015% gel
Study: NCT01497210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EASH dressing
Description: Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
Study: NCT01236755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-vision glasses
Description: Daily wear of glasses to correct vision in the first seven months of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ortho-k lenses
Description: Nightly wear of lenses to correct vision in day time in the second seven months of the study
Study: NCT01080313

Intervention type: OTHER
Intervention: Therapy for head and neck cancer
Description: radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
Study: NCT01176292

Intervention type: DEVICE
Group type: OTHER
Intervention: Rotating Platform High-Flex Cruciate Substituting TKA

Intervention type: DEVICE
Group type: OTHER
Intervention: Rotating Platform Cruciate Substituting TKA
Study: NCT03093675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELELAP ALF-X Robotic Surgical System
Description: The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
Study: NCT00838266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)
Description: Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mouthrinse containing non-active component
Description: Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
Study: NCT00805935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone vaginal insert
Description: 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal insert
Description: 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
Study: NCT01013233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no intervention
Study: NCT02574871

Intervention type: OTHER
Intervention: Psychological and biological data collection
Description: Psychological and biological data collection for identification of the chronic stress presence
Study: NCT04209309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Study: NCT00590954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4.
Study: NCT00072150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT01040585

Intervention type: DRUG
Intervention: Linezolid
Description: Treatment for VAP as indication approved and as physician criterium.
Study: NCT00749723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa, carboplatin, etoposide
Description: high dose chemotherapy followed by to autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide, thiotepa
Description: high dose chemotherapy followed by autologous stem cell transplantation
Study: NCT04441333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AspivixTM cervical vacuum tenaculum
Description: Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
Study: NCT02030171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functionnal reeducation
Description: Specific functionnal reeducation for chronic low back pain
Study: NCT02531997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotic Relaxation Therapy
Description: There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
Study: NCT02531997

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Muscle Relaxation
Description: Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
Study: NCT01691404

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin
Description: Subjects will be asked to consume supplements containing 100mg of epicatechin daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Subjects will be asked to consume 160mg of quercetin-3-glucoside daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be asked to consume capsules containing placebo (cellulose) daily
Study: NCT00257556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotrophin
Description: 150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa
Description: 150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Study: NCT01933048

Intervention type: DRUG
Group type: OTHER
Intervention: FluMist
Description: FluMist Intranasal Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist Intranasal Vaccine
Study: NCT00380393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK malaria vaccine 257049 Vaccine
Description: 3 dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine
Description: 3 dose intramuscular injection
Study: NCT03126994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhysioWave Cardiovascular Analyzer
Description: Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
Study: NCT00749723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: autologous stem cell transplantation following HD-chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: autologous stem cell transplantation following HD-chemotherapy
Study: NCT03126994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtCor XCEL PWA & PWV
Description: Measurement of Pulse Wave Velocity and Pulse Rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detecto SOLO
Description: Measurement of Body Weight and BMI